GlobalData on MSN

Silver Creek’s stroke hopeful yields mixed results in Phase II trial

If approved, the targeted IGF-1 fusion protein would become the only treatment available for late-window stroke patients ...

Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke

Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after ...
The New England Journal of Medicine

Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...
News-Medical.Net on MSN

Study highlights the emotional and social challenges of stroke recovery

Nirupama Yechoor, MD, MSC, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper ...
The New England Journal of Medicine

Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke

Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular reocclusion may occur after intravenous thrombolysis and may be preventable with ...